Drug Profile
Research programme: exosome therapeutics - ArunA Biomedical
Latest Information Update: 11 Oct 2022
Price :
$50
*
At a glance
- Originator ArunA Biomedical
- Developer ArunA Biomedical; Augusta University; University of Georgia
- Class Exosome therapies; Neuroprotectants; Vascular disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Neurodegenerative disorders; Stroke
Highest Development Phases
- Preclinical Traumatic brain injuries
- Research Multiple sclerosis; Parkinson's disease
- No development reported CNS disorders; Neurodegenerative disorders; Stroke
Most Recent Events
- 06 Oct 2022 ArunA Biomedical announces intention to file IND for Stroke in second quarter of 2023
- 14 Jun 2022 ArunA Biomedical and University of Georgia has patent protection for the composition of neural exosomes and their use as a therapeutic for neurological diseases and disorders in Japan
- 31 May 2022 Preclinical trials in Traumatic brain injuries in USA (Parenteral)